Astellas Pharma Europe is an established, recognised global category leader in urology and is dedicated to improving the lives of people around the world through the introduction of innovative and reliable pharmaceutical products.
Astellas Pharma provides a portfolio of urological medicines including Europe’s leading treatment for overactive bladder (OAB) and the world’s number one treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
OAB is a serious urological condition that affects nearly 1 in 5 men and women across Europe, disrupting normal life because of the sudden and compelling need to go to the toilet during the day or the night. It is a significantly under diagnosed condition that may result in incontinence, and meeting this unmet medical need is a serious focus for Astellas both with its current portfolio and its ongoing research and development efforts.
LUTS and BPH are two other serious urological conditions, with BPH affecting more than 50% of men aged 50 years or over and more than 90% of men over the age of 80 years. Like OAB, both conditions are disruptive to normal life causing the frequent and urgent need to go to the toilet, and both are often significantly under diagnosed. Astellas has developed a treatment for LUTS, associated with BPH, which relaxes the bladder neck as well as the prostate urethra and smooth muscle and improves bladder storage to reduce the symptoms of the condition. Astellas continues to conduct research within these conditions.
Astellas is dedicated to finding new medicines to address unmet medical needs through its extensive, continuous research and development. Through its major R&D programme, the company is developing in many therapy areas. Within urology, Astellas is developing treatments for conditions such as OAB, LUTS and BPH where a high level of unmet medical need exists. The company maintains a substantial investment in its research programme committing more than 20% of its net sales to its ongoing R&D effort and actively pursues alliances with companies and scientists targeting drugs in focussed therapy areas, for example in urology, uro-gynaecology and uro-oncology.
Astellas Europe remains committed to education amongst urologists and continues to support numerous local country scientific meetings and international symposia at key congresses in Europe. Astellas works closely with independent bodies like the European Association of Urologists (EAU) on major programmes, like the Young Urologist programme and the European Urology Residents Education Programme (EUREP) for newly qualified residents.
As a recognised leading pharmaceutical company, Astellas Pharma Europe continues to pioneer the development of medicines for unmet urological conditions including Overactive Bladder (OAB), lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).